AUTHORS
Cameron S. Bader, PhD, Amalia Perna, PhD2, Bettina P. Iliopoulou, PhD3, Matteo Santoro, PhD4, Marcus Schonemann, BS5, Thomas J. Montine, MD, PhD6, Everett Meyer, MD, PhD7
AFFILIATIONS
1 Stanford University, Stanford, California, United States, University of Wisconsin, Madison, Madison, Wisconsin, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
ABSTRACT
Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disease and is increasing exponentially as the world’s population achieves historic longevity. During the progression of AD, colony-stimulating factor 1 receptor (CSF1R) dependent microglia can adopt irreversible inflammatory states that contribute to neurodegeneration. Microglia are brain-resident myeloid cells that were thought to singularly derive from the yolk sac during development, but our recent work strongly supports the notion that human bone marrow-derived cells can take up brain residence as microglia-like cells. We therefore hypothesize that replacement of proinflammatory microglia with healthy donor bone marrow-derived cells could mitigate neuroinflammatory responses that contribute to AD neurodegeneration. Further, we have established a minimally-toxic, nonmyeloablative bone marrow transplant (BMT) regimen in mice and humans that is currently used clinically in combined kidney and hematopoietic cell transplantation. Here, we combine our nonmyeloablative BMT strategy with the CSF1R inhibitor PLX3397 to sequentially engraft donor hematopoietic cells in the bone marrow and periphery followed by donor-derived microglia-like cells in the mouse brain.
First, to establish the ability of CSF1R inhibition to create physical space for bone marrow-derived microglia-like cells to engraft in the brain, C3H mice were treated with PLX3397 for 14 days. PLX3397 treatment resulted in significant reductions of total CD11b+ myeloid frequencies and numbers amongst all hematopoietic cells in the peripheral blood, spleen, and bone marrow (p < 0.05 for each) and nearly complete depletion of CD45+CD11b+ microglia in the perfused brain compared to untreated mice (0.49% vs. 14.7%, p < 0.001).
We then combined our nonmyeloablative BMT strategy with PLX3397 treatment with the goal of engrafting donor-derived microglia-like cells in the brain. C3H mice were conditioned with fractionated total lymphoid irradiation (TLI), low-dose total body irradiation (TBI), and anti-thymocyte serum (ATS), and PLX3397 was administered for 14 days after BMT. Recipients exhibited high multilineage peripheral donor chimerism as early as 2 weeks post-BMT which was persistent in the peripheral blood, spleen, lymph nodes, and bone marrow through 8 weeks after transplant (mean = 79% donor). In the brain, post-transplant PLX3397 treatment resulted in high donor chimerism amongst CD45+CD11b+ microglia by flow cytometry compared to mice that did not receive PLX3397 (88.8% vs. 5.3%, p < 0.001) and immunofluorescence imaging demonstrated engraftment in all regions of the brain. These data demonstrate that establishing peripheral donor chimerism prior to microglia depletion can achieve robust engraftment of microglia-like cells in the mouse brain.
To examine how donor and bone marrow-derived microglia-like cells differ from brain resident microglia, we sorted donor-derived microglia-like cells (CD45+CD11b+GFP+) and recipient microglia (CD45+CD11b+GFP-) and captured each population for single-cell RNA-seq (n=5 mice/group). Transcriptomic analysis identified Itga4 (encoding CD49d) as a specific marker of bone marrow-derived microglia-like cells in the brain. Donor microglia-like cells also expressed significantly higher levels of MHC II genes (ex: H2-Ab1) and the M2 macrophage marker Mrc1 (encoding CD206) compared to brain-resident microglia. We then interrogated these results at the protein level by flow cytometry and confirmed that donor-derived GFP+ microglia-like cells were significantly more likely to express CD49d compared to recipient cells (61.7% vs. 14.8%, p < 0.001), highlighting its potential as a marker of bone marrow-derived myeloid cells in the brain. Flow cytometry also corroborated increased expression of MHCII (55.5% vs. 5.7%, p < 0.001) and CD206 (32.5% vs. 12.8%, p < 0.001) on donor microglia-like cells, suggesting an immunologically active and immunomodulatory M2 macrophage phenotype which may control neuroinflammation.
Lastly, preliminary activity chamber behavioral testing in the PS19 tau-driven mouse model of AD suggests an improvement in cognitive ability amongst mice receiving BMT and PLX3397 compared to untreated controls two months post-BMT. Ongoing studies are therefore conducting longitudinal behavioral testing in mice to determine whether this clinically relevant BMT strategy can prevent or slow neurodegeneration in pathologic tau and amyloid beta mouse models of AD.
DISCLOSURES
Cameron S. Bader, PhD: Orca Bio, Inc. - Honoraria